GleamWall
中文EN

INTI Inhibitor Therapeutics, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1042418 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY7.0%
TTM EPS YoY0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-188.4%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets1,373.4%
Debt / equity—
Current ratio0.53x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.89x
Accruals ratio-21.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$1.70M$1.76M
SG&A expense$1.73M$1.90M
Operating income-$3.43M-$3.66M
Net income-$3.30M-$3.34M
EPS (basic)-0.02-0.02
EPS (diluted)-0.02-0.02
Weighted avg. shares (diluted)172.51M172.26M
Balance sheet
Cash & equivalents$2.38M$5.61M
Current assets$2.45M$5.69M
Total assets$2.51M$5.69M
Current liabilities$766,330$709,618
Short-term debt$24,724—
Long-term debt$36,889—
Total debt$61,613—
Total liabilities$3.80M$3.71M
Shareholders' equity-$1.29M$1.99M
Net debt-$2.31M—
Shares outstanding172.57M172.32M
Cash flow statement
Operating cash flow-$3.23M-$3.23M
Stock-based compensation$23,385$40,250

Free plan shows the latest 2 periods; Pro shows all 14 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.